MKKGY (Merck KGaA) Total Liabilities : $22,597 Mil (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Merck KGaA Total Liabilities?

Merck KGaA's Total Liabilities for the quarter that ended in Dec. 2024 was $22,597 Mil.

Merck KGaA's quarterly Total Liabilities increased from Jun. 2024 ($22,883.75 Mil) to Sep. 2024 ($24,138.74 Mil) but then declined from Sep. 2024 ($24,138.74 Mil) to Dec. 2024 ($22,596.86 Mil).

Merck KGaA's annual Total Liabilities declined from Dec. 2022 ($23,866.53 Mil) to Dec. 2023 ($23,707.74 Mil) and declined from Dec. 2023 ($23,707.74 Mil) to Dec. 2024 ($22,596.86 Mil).

Merck KGaA Total Liabilities Historical Data

The historical data trend for Merck KGaA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck KGaA Total Liabilities Chart

Merck KGaA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

30,144.77

27,057.63

23,866.53

23,707.74

22,596.86

Merck KGaA Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															23,707.74	23,293.48	22,883.75	24,138.74	22,596.86

Merck KGaA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Merck KGaA's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11826.178	+	(7327.749	+	1356.021
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2048.168	+	38.743)
	=	22,597

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	53996.859	-	31400
	=	22,597

Merck KGaA's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11826.178	+	(7327.749	+	1356.021
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2048.168	+	38.743)
	=	22,597

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	53996.859	-	31400
	=	22,597

Merck KGaA Total Liabilities Related Terms

Thank you for viewing the detailed overview of Merck KGaA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck KGaA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (OTCPK:MKKGY) » Definitions » Total Liabilities

Traded in Other Exchanges

MKGAF:USA 1MRK:Italy MRKd:UK 0O14:UK MRKC:Germany MRK:Germany MRKC:Germany MRK:Germany MRK:Germany MRK:Germany MRK:Bulgaria MRCK:Austria

Address

Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293

Website

https://www.emdgroup.com

Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.